Lundbeck Korea – Oh Pil-Soo, Managing Director
Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. …
Bioneer Corp., founded in 1992 as the first bio-venture in South Korea, is moving forward to a full-fledged molecular biotechnology company on the strength of the R&D infrastructure and intellectual properties.
Since beginning the home production of synthetic oligonucleotides and PCR enzymes with its proprietary technology for the first time in Korea, Bioneer has continuously built up expertise in molecular diagnostics and RNAi therapeutics. Bioneer is currently providing total solutions for molecular diagnostics in various disease areas through an integrated platform of reagents, instruments and analysis software. Bioneer’s SAMiRNA™ is a new paradigm of RNAi therapeutics in terms of being a much more efficient carrier compared to the conventional methods to deliver siRNA to the inside of a target cell.
Bioneer has vertically integrated genomic technology-based businesses, which provides competitive advantages in the market such as price competitiveness, product development efficiency and a high level of control. Today, Bioneer is operating businesses in the following three domains: Research-use products in genomics, biotechnology, molecular biology, etc.; Molecular diagnostic reagents, instruments and software; New development based on RNAi.
Contact details
Webpage: www.bioneer.com
Address: 8-11, Munpyeongseo-ro, Daedeok-gu, Daejeon 306-220, Republic of Korea
Tel: +82-42-930-8777
Fax: +82-42-930-8688
Email: sales@bioneer.com
Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. …
Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation…
The American Chamber of Commerce in Korea (Amcham Korea) was established in 1953 and has a long history in developing bilateral economic and trade relations between the US and Korea. Amy…
Cho Chan-Hwui, president of the Korean Pharmaceutical Association (KPA), discusses the major hurdles that pharmacists in Korea must overcome today, and the increased focus on prescription by INN. How…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of…
The European Chamber of Commerce in Korea (ECCK) was founded in 2012, in order to represent the interests of European businesses in Korea. Christoph Heider, secretary general of ECCK, discusses…
Yuhan is one of the largest and fastest growing pharmaceutical companies in South Korea, with a long history in the sector. In your view, what are the main elements that…
South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical trial industry today? The…
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting…
Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of…
See our Cookie Privacy Policy Here
